166 related articles for article (PubMed ID: 23814490)
21. Deep PIM kinase substrate profiling reveals new rational co-therapeutic strategies for acute myeloid leukemia.
Joglekar T; Chin A; Voskanian-Kordi A; Seungchul B; Raja A; Rege A; Huang W; Kane MA; Laiho M; Webb T; Fan X; Rubenstein M; Bieberich CJ; Li X
Blood Adv; 2024 May; ():. PubMed ID: 38739710
[TBL] [Abstract][Full Text] [Related]
22. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
Atalay P; Ozpolat B
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
[TBL] [Abstract][Full Text] [Related]
23. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
[TBL] [Abstract][Full Text] [Related]
24. Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis.
Rosenberger G; Li W; Turunen M; He J; Subramaniam PS; Pampou S; Griffin AT; Karan C; Kerwin P; Murray D; Honig B; Liu Y; Califano A
Nat Commun; 2024 May; 15(1):3909. PubMed ID: 38724493
[TBL] [Abstract][Full Text] [Related]
25. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.
Letson CT; Balasis ME; Newman H; Binder M; Vedder A; Kinose F; Ball M; Kruer T; Quintana A; Lasho TL; Finke CM; Almada LL; Grants JM; Zhang G; Fernandez-Zapico ME; Gaspar-Maia A; Lancet J; Komrokji R; Haura E; Sallman DA; Reuther GW; Karsan A; Rix U; Patnaik MM; Padron E
Clin Cancer Res; 2023 Aug; 29(15):2919-2932. PubMed ID: 37223910
[TBL] [Abstract][Full Text] [Related]
26. Correction to 'In vivo analysis of Pim-1 deficiency'.
Nucleic Acids Res; 2023 Oct; 51(18):10107. PubMed ID: 37650643
[No Abstract] [Full Text] [Related]
27. Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients.
Peng YH; Li JJ; Xie FW; Chen JF; Yu YH; Ouyang XN; Liang HJ
PLoS One; 2013; 8(10):e76693. PubMed ID: 24116137
[TBL] [Abstract][Full Text] [Related]
28. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.
Zhao B; Liu L; Mao J; Zhang Z; Wang Q; Li Q
Cell Death Dis; 2018 Feb; 9(3):307. PubMed ID: 29472550
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome profiling of human col\onic cells exposed to the gut pathobiont Streptococcus gallolyticus subsp. gallolyticus.
Pasquereau-Kotula E; du Merle L; Sismeiro O; Pietrosemoli N; Varet H; Legendre R; Trieu-Cuot P; Dramsi S
PLoS One; 2023; 18(11):e0294868. PubMed ID: 38033043
[TBL] [Abstract][Full Text] [Related]
30. PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Torres-Ayuso P; Katerji M; Mehlich D; Lookingbill SA; Sabbasani VR; Liou H; Casillas AL; Chauhan SS; Serwa R; Rubin MR; Marusiak AA; Swenson RE; Warfel NA; Brognard J
Cell Chem Biol; 2024 Feb; 31(2):326-337.e11. PubMed ID: 38016478
[TBL] [Abstract][Full Text] [Related]
31. Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer.
Park YS; Kim J; Ryu YS; Moon JH; Shin YJ; Kim JH; Hong SW; Jung SA; Lee S; Kim SM; Lee DH; Kim DY; Yun H; You JE; Yoon DI; Kim CH; Koh DI; Jin DH
Cancer Biol Ther; 2023 Dec; 24(1):2246208. PubMed ID: 37621144
[TBL] [Abstract][Full Text] [Related]
32. Targeting Myc-driven stress addiction in colorectal cancer.
Saeed H; Leibowitz BJ; Zhang L; Yu J
Drug Resist Updat; 2023 Jul; 69():100963. PubMed ID: 37119690
[TBL] [Abstract][Full Text] [Related]
33. Plantaricin BM-1 decreases viability of SW480 human colorectal cancer cells by inducing caspase-dependent apoptosis.
Wang H; Jin J; Pang X; Bian Z; Zhu J; Hao Y; Zhang H; Xie Y
Front Microbiol; 2022; 13():1103600. PubMed ID: 36687624
[TBL] [Abstract][Full Text] [Related]
34. Targeting PIM Kinases to Improve the Efficacy of Immunotherapy.
Clements AN; Warfel NA
Cells; 2022 Nov; 11(22):. PubMed ID: 36429128
[TBL] [Abstract][Full Text] [Related]
35. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
Li X; Moreira DC; Bag AK; Qaddoumi I; Acharya S; Chiang J
Neuro Oncol; 2023 Apr; 25(4):750-760. PubMed ID: 36260562
[TBL] [Abstract][Full Text] [Related]
36. Saccharomonosporine A inspiration; synthesis of potent analogues as potential PIM kinase inhibitors.
AboulMagd AM; Hassan HM; Sayed AM; Abdelmohsen UR; Abdel-Rahman HM
RSC Adv; 2020 Feb; 10(12):6752-6762. PubMed ID: 35493904
[TBL] [Abstract][Full Text] [Related]
37. Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28.
Toth RK; Solomon R; Warfel NA
Cells; 2022 Mar; 11(6):. PubMed ID: 35326457
[TBL] [Abstract][Full Text] [Related]
38. Relationship between the transcriptional expression of PIM1 and local control in patients with head and neck squamous cell carcinomas treated with radiotherapy.
León X; García J; Pujol A; de Juan J; Vásquez R; Quer M; Camacho M
Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3679-3684. PubMed ID: 34993612
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of miR-3135b reduces sensitivity to 5-fluorouracil in colorectal cancer by direct repression of PIM1.
Wang Y; Cui X; Ma S; Zhang H
Exp Ther Med; 2021 Oct; 22(4):1151. PubMed ID: 34504596
[TBL] [Abstract][Full Text] [Related]
40. The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma.
Crudele F; Bianchi N; Astolfi A; Grassilli S; Brugnoli F; Terrazzan A; Bertagnolo V; Negrini M; Frassoldati A; Volinia S
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
